Shares in weight loss drugmaker Eli Lilly fall on disappointing sales

Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales

US group revises down upper end of full-year revenue estimates

Business - Financial Times - October 30

Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed

Eli Lilly blamed the misses on drug wholesalers cutting inventory of Zepbound and Mounjaro.

Business - CNBC - October 30

Chipotle misses revenue estimates as same-store sales growth disappoints

Chipotle's same-store sales rose 6% in the third quarter, just missing Wall Street's expectations.

Business - CNBC - October 30

Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.

Business - MarketWatch - October 30

Lilly's weight loss drug shortage deemed over, but hurdles remain

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Jim Cramer identifies an interesting buy level for our worst performing Big Tech stock this year

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.

Business - CNBC - October 31

Amgen says no concerns around weight loss drug’s bone density data after stock falls

Analysts chewed over early data showing the highest dose of Amgen's MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.

Business - CNBC - November 13

Eli Lilly's quarter was messy. What to do with the stock is more clear-cut

We're upgrading our rating on the drugmaker to a buy-equivalent 1.

Business - CNBC - October 30

Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial

Eli Lilly’s cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.

Business - CNBC - Yesterday

Serco shares fall on Australian contract loss and changes to UK national insurance

UK operator of prisons and asylum accommodation expects a combined £38mn hit in 2025

World - Financial Times - November 8

Drugmaker shares drop after RFK Jr. tapped to lead HHS

Shares in several pharmaceutical and biotechnology companies have fallen since President-elect Trump announced Thursday that he had tapped vaccine skeptic Robert F. Kennedy Jr. to lead the ...

Politics - The Hill - 5 days ago

Applied Materials Offers Modest Sales Outlook on Slowdown of Chinese Market; Shares Fall

Applied Materials forecasts revenue growth of between 8% and 12% across its core semiconductor-systems business and its applied global-services segment, respectively, but also a 28% drop in display ...

Business - The Wall Street Journal - 6 days ago

Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase manufacturing capacity.

Business - CNBC - October 30

Here's why Eli Lilly bounced back, plus mega-caps lag while staples stocks rise

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Business - CNBC - November 8

How we're thinking about Eli Lilly after Trump picked obesity-drug critic RFK Jr. to run HHS

Robert F. Kennedy Jr. has been a vocal critic of obesity drugs belonging to the fast-growing GLP-1 class.

Business - CNBC - 5 days ago

Nurse’s death linked to approved weight-loss drug

Susan McGowan from North Lanarkshire died two weeks after taking the drug tirzepatide, brand name Mounjaro.

Deutsche Bank shares fall on doubling of third-quarter loan losses but profits rise

Deutsche Bank’s pre-tax profits were lifted by a reduction in the provisions it has set aside to settle litigation related to its Postbank acquisition

Business - MarketWatch - October 23

L’Oréal sales disappoint due to weak Chinese demand

Revenue at world’s biggest beauty company grew 3.4 per cent in third quarter, when analysts expected 6 per cent

Business - Financial Times - October 22

AbbVie shares tumble after schizophrenia drug disappoints

US pharma group says patients who took Emraclidine in clinical trials failed to show a significant decline in symptoms

Business - Financial Times - November 11

Target shares tumble as retailer’s holiday forecast disappoints

US retailer blames muted sales of non-essential items and rising costs

World - Financial Times - Yesterday

Oil ends down on the day, up for the week on conflicting supply-demand prospects

Oil futures finished lower on Friday, with China’s latest round of stimulus measures failing to lift expectations for energy demand in the face of President-elect Donald Trump’s support for more ...

Business - MarketWatch - November 8

Jones disputes notion McCarthy has lost Cowboys

After watching his team fall to 3-7 with a 34-10 loss to the Texans on Monday, Cowboys owner Jerry Jones told reporters that the franchise "didn't anticipate the record," but scoffed at the notion ...

Sports - ESPN - Yesterday

Hoping for a weight-loss pill? It could get closer to reality next week.

Viking Therapeutics Inc.’s stock rose 2% Friday as excitement continued to build about data on its oral weight-loss drug the company will present at the upcoming Obesity Week event.

Business - MarketWatch - November 2

The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide — while adding great heft to the economy of Novo Nordisk’s home country, Denmark.

Weight loss drug industry injects wealth into Novo Nordisk home country

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great heft to the economy of Novo Nordisk's home country, Denmark.

Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial

The stock, which enjoys the unusual position of having all buy ratings from the 13 analysts offering coverage on FactSet, has been on a tear this year, gaining 270% to date in 2024.

Business - MarketWatch - November 4

Counterfeit weight loss drugs sold online as demand for cheaper options grows

A surge in counterfeit versions of popular weight loss drugs is raising health concerns. U.S. Customs is intercepting fake medications with potentially harmful effects. Tom Hanson reports on the ...

Counterfeit weight loss drugs feed demand for cheaper options

Record demand for Ozempic, Wegovy and other weight loss drugs is fueling a surge of dangerous knockoffs.

Latest in Shares in weight loss drugmaker Eli Lilly fall on disappointing sales